GERN Earnings

GERN reported its FY2025Q3 earnings on 2025-11-05, showcasing a revenue of 47.00M against an estimate of 53.00M, resulting in a -11.46% surprise. The EPS was -0.03, surpassing the expected -0.03 by 0% . The stock experienced a -5.22% price change on the earnings day and a 0.87% change over the next five days, reflecting market reactions to the results.

Following GERN's FY2025Q3 earnings announcement on 2025-11-05, the stock price moved by -5.22% on the day of the release. Over the subsequent five days, it saw a 0.87% change. Historically, GERN's stock price tends to shift by an average of +6.29% in the 10 days leading up to earnings and -0.88% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate GERN’s annual revenue to reach 51.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.89% and EPS estimates Revise Downward by -13.4% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between GERN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.89%, while EPS estimates moved Revise Downward by -13.4% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GERN's stock price typically moves by +6.29% in the 10 days before its earnings and -0.88% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 51.00M.

The earnings call reveals several negative factors: a 3% demand decrease for RYTELO, high operating expenses, and competitive pressures. While there is a significant increase in net product revenue, the timeline for the IMpactMF Phase III trial is lengthy, delaying potential market impact. The Q&A section highlights management's avoidance of specific guidance, which may concern investors. Although there is a 15% growth in prescribing accounts, the overall sentiment is negative due to financial pressures, competitive landscape, and lack of clarity on future growth timelines.